KX2-391 Ointment 1%

DRUG3 trials

Sponsors

Almirall, S.A., Athenex, Inc.

Conditions

Actinic KeratosesActinic Keratosis

Phase 1

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

CompletedNCT03575780

Athenex, Inc.Actinic Keratoses

Start: 2018-09-07End: 2019-10-10Updated: 2019-12-09

Phase 3

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

CompletedNCT03285490

Almirall, S.A.Actinic Keratosis

Start: 2017-09-15End: 2019-04-24Updated: 2021-03-10

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

CompletedNCT03285477

Almirall, S.A.Actinic Keratoses

Start: 2017-09-18End: 2019-04-24Updated: 2021-04-13

Related Papers

Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase‐<scp>III</scp> trials and the real‐life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022

Journal of the European Academy of Dermatology and Venereology2023-12-209 citations

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis

New England Journal of Medicine2021-02-10152 citations